Toxicology Reagent DRI® (5390012202) | USA MedPremium
Toxicology Reagent DRI® Benzodiazepine (BZO) For MedTest 200 Ensemble, 480 Ensemble and 800 Ensemble Systems
USAMP#85353840SKU: 5390012202DRI®
Product Spotlight
The DRI® Benzodiazepine Assay is a homogeneous enzyme immunoassay intended for the qualitative and/or semi-quantitative determination of the presence of benzodiazepines and their metabolites in human urine at a cutoff concentration of 200 ng/mL
Qualitative or semi-quantitative options for results
Excellent correlation to GC/MS
These liquid, ready-to-use assays offer applications for an array of clinical chemistry analyzers and have been field-tested on a wide range of analyzers
The semi-quantitative mode is for the purpose of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as Liquid Chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures
